What did William Blair do on February 10, 2026?

William Blair upgraded Nektar Therapeutics to **Outperform** on February 10, 2026 at **11:26 AM**. The upgrade marks stronger conviction versus its prior Market Perform rating and may influence short-term investor sentiment.

How do the H.C. Wainwright and BTIG moves affect NKTR price targets?

H.C. Wainwright raised its NKTR price target to **$165** from **$135**, while BTIG lifted its target to **$151** from **$118**. Both firms maintained Buy ratings, indicating they expect upside versus current market levels.

What should investors make of the NKTR analyst rating mix?

The mix—one upgrade and two maintained Buys with higher targets—signals rising analyst confidence but not consensus certainty. Investors should weigh catalysts, timelines, and volatility before changing positions.

What is Meyka AI’s current grade for NKTR and what does it mean?

Meyka AI rates NKTR with a grade of **B+**, based on benchmark comparison, sector performance, growth, key metrics, and analyst consensus. This grade is informational and not financial advice.

Analyst Ratings

BTIG Maintains Buy on Nektar Therapeutics (NKTR) Feb 2026

ByHuzaifa Zahoor February 11, 2026February 11, 2026

William Blair upgraded Nektar Therapeutics to Outperform on February 10, 2026, setting the tone for three analyst moves that day. The NKTR analyst rating shifts included two maintained Buy calls with raised price targets from H.C. Wainwright and BTIG and one outright upgrade from William Blair. These moves reflect renewed analyst confidence after recent setbacks. Investors should note the timing and price targets, as ratings now sit alongside a market cap of $1,139,128,984, and may influence sentiment in the near term.